logo
[breadcrumb_custom]

Tag: MTNB Shares

Stock

Matinas Biopharma Holdings Inc (MTNB) Stock: The Story of a 52-Week Stock Range

The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Matinas Biopharma Holdings Inc’s current trading price is -77.34% away from its 52-week high, while its distance from the 52-week low is 82.86%. The stock’s price range for this period has been between $0.11 and $0.89 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 0.55 million for the day, a number notably lower than the average daily volume of 1.55 million over the last three months. Matinas Biopharma Holdings Inc ‘s stock

VIPS stock
Industry

The Future of Matinas Biopharma Holdings Inc: Analyzing MTNB

In terms of market performance, Matinas Biopharma Holdings Inc had a fairly uneven. The highest value for the stock in the past year was $0.89 on 10/11/23, and the lowest value was recorded at $0.11 on 08/10/23. 52-week price history of MTNB Stock Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Matinas Biopharma Holdings Inc’s current trading price is -58.45% away from its 52-week high, while its distance from the 52-week low is 235.27%. The stock’s price range during the 52-week period has remained between

SLGG
News

Company’s Banking Stock: Dissecting a 34.10% Quarterly Revenue Decline Amid Growth

Matinas Biopharma Holdings Inc’s stock market performance has been somewhat irregular. The 1-year high for the company’s stock was recorded at $0.89 on 10/11/23, with the lowest value being $0.11 on 08/10/23. 52-week price history of MTNB Stock Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Matinas Biopharma Holdings Inc’s current trading price is -67.39% away from its 52-week high, while its distance from the 52-week low is 163.10%. The stock’s price range for this period has remained between $0.11 and $0.89.

ZM Stock
Finance

Matinas Biopharma Holdings Inc (MTNB) Stock: A Comprehensive 52-Week Review

Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Matinas Biopharma Holdings Inc’s current trading price is -68.10% away from its 52-week high, while its distance from the 52-week low is 157.39%. The stock’s price range over this period has fluctuated between $0.11 and $0.89. The company, operating within the financial sector, had a trading volume of approximately 18.61 million for the day, which was noticeably higher than the average daily share volume of 0.99 million over the last 3 months. In terms of market performance,

Stock

Matinas Biopharma Holdings Inc (MTNB) Stock: A Year of Stock Market Ups and Downs

Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Matinas Biopharma Holdings Inc’s current trading price is -66.29% away from its 52-week high, while its distance from the 52-week low is 171.99%. The stock’s price range over this period has fluctuated between $0.11 and $0.89. The company, operating within the financial sector, had a trading volume of approximately 3.83 million for the day, which was noticeably higher than the average daily share volume of 0.98 million over the last 3 months. The market performance of Matinas

THMO
News

Matinas Biopharma Holdings Inc (MTNB) Stock: From Low to High in 52 Weeks

A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Matinas Biopharma Holdings Inc’s current trading price is -73.54% away from its 52-week high, while its distance from the 52-week low is 113.51%. The stock’s price range for this time frame has been between $0.11 and $0.89. The trading volume of the company’s shares in the Healthcare reached around 0.94 million for the day, which was evidently lower than the average daily volume of 0.97 million over the last three months. In terms of market performance, Matinas Biopharma Holdings